Trial Profile
Phase Ib - II Study of Entospletinib (ENTO) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With aaIPI≥1 Treated by Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Entospletinib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 10 Jul 2020 Status changed from active, no longer recruiting to discontinued. According to ClinicalTrials.Gov this study is terminated. Reason the study was stopped: Stop of drug development.
- 20 Dec 2019 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 21 May 2019 Status changed from recruiting to active, no longer recruiting.